13F Holdings
中文EN

COLL COLLEGIUM PHARMACEUTICAL, INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 1267565 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY7.7%
TTM net income YoY-34.7%
TTM EPS YoY-37.9%
Revenue 3-yr CAGR14.2%
Net income 3-yr CAGR61.8%

Margins

Gross margin59.0%
Operating margin15.2%
Net margin4.7%
FCF margin41.3%
EBITDA margin15.7%

Returns

ROE13.4%
ROA2.1%
ROIC (approx.)81.3%
Asset turnover0.44x

Leverage & solvency

Liabilities / assets85.9%
Debt / equity0.00x
Current ratio1.01x
Interest coverage1.62x

Cash quality & payout

Operating cash flow / net income8.86x
Accruals ratio-16.2%
Payout ratio—
Capex / revenue0.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$780.57M$631.45M$566.77M$463.93M$276.87M
Cost of revenue$317.31M$254.10M$240.60M$254.44M$126.25M
Gross profit$463.26M$377.34M$326.17M$209.49M$150.62M
R&D expense—$0$0$3.98M$9.45M
SG&A expense$284.80M$210.36M$159.21M$172.19M$118.96M
Operating income$179.64M$169.90M$166.96M$33.32M$17.63M
Interest expense$82.31M$73.97M$83.34M$63.21M$21.01M
Pretax income$92.62M$98.57M$75.73M-$28.85M-$3.37M
Income tax$29.75M$29.38M$27.58M-$3.85M-$74.89M
Net income$62.87M$69.19M$48.16M-$25.00M$71.52M
EBITDA$183.82M$173.75M$170.46M$36.00M$19.36M
EPS (basic)1.982.141.43-0.742.05
EPS (diluted)1.731.861.29-0.741.86
Weighted avg. shares (diluted)39.70M40.42M41.79M33.83M41.05M
Balance sheet
Cash & equivalents$231.25M$96.61M$238.95M$176.24M$188.97M
Short-term investments$155.43M$92.20M$71.60M$0—
Receivables$211.33M$228.54M$179.53M$183.12M$105.84M
Inventory$40.91M$35.56M$32.33M$46.50M$17.39M
Current assets$691.41M$482.26M$537.60M$419.99M$315.54M
PP&E, net$12.01M$14.33M$15.98M$19.52M$19.49M
Goodwill$145.93M$162.33M$133.86M$133.69M—
Intangibles$669.51M$891.40M$421.71M$567.47M$268.72M
Total assets$1.66B$1.66B$1.14B$1.17B$692.08M
Current liabilities$440.03M$509.51M$457.92M$433.73M$279.57M
Total liabilities$1.36B$1.43B$947.88M$979.29M$489.15M
Shareholders' equity$301.68M$228.84M$195.43M$194.84M$202.93M
Shares outstanding31.71M31.44M31.87M33.85M33.66M
Cash flow statement
Operating cash flow$329.32M$204.98M$274.75M$124.23M$103.56M
Capital expenditure$1.74M$1.65M$461,000$1.62M$1.94M
Free cash flow$327.58M$203.33M$274.29M$122.61M$101.61M
Investing cash flow-$63.53M-$287.76M-$70.81M-$573.69M-$1.94M
Financing cash flow-$110.25M-$60.60M-$140.18M$436.72M-$89.30M
Depreciation & amortization$4.18M$3.86M$3.50M$2.68M$1.74M
Stock-based compensation$41.91M$32.40M$27.14M$22.87M$24.25M
Share buybacks$25.10M$60.02M$75.00M$14.06M$47.86M

Free plan shows the latest 5 periods; Pro shows all 13 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.